HODGKIN'S LYMPHOMA
Clinical trials for HODGKIN'S LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new HODGKIN'S LYMPHOMA trials appear
Sign up with your email to follow new studies for HODGKIN'S LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
PET scans could spare hodgkin patients from extra chemo
Disease control CompletedThis study tested whether using an early PET scan after two rounds of chemotherapy can help doctors choose the right treatment for people with advanced Hodgkin lymphoma. Patients whose scan showed a good response got a milder chemo, while those with less response continued strong…
Matched conditions: HODGKIN'S LYMPHOMA
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New dosing schedule of immunotherapy shows promise for hard-to-treat lymphomas
Disease control CompletedThis study tested the drug pembrolizumab (Keytruda) given every 6 weeks to 66 adults whose Hodgkin lymphoma or primary mediastinal large B-cell lymphoma had come back or not responded to prior treatment. The main goal was to see how many patients had their tumors shrink or disapp…
Matched conditions: HODGKIN'S LYMPHOMA
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug may spare hodgkin patients from harsh chemo before transplant
Disease control CompletedThis study tested whether a targeted drug called brentuximab vedotin (SGN-35) could replace the standard ICE chemotherapy before a stem cell transplant in 66 people with relapsed or refractory Hodgkin lymphoma. The drug targets cancer cells and has fewer side effects than ICE. Pa…
Matched conditions: HODGKIN'S LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug may reduce transplant complications in blood cancer patients
Disease control CompletedThis study tested whether the drug palifermin could make stem cell transplants safer and reduce chronic graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Thirty-four adults with blood cancers received palifermin before transplan…
Matched conditions: HODGKIN'S LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC